An overview on 5α-reductase inhibitors

@article{Aggarwal2010AnOO,
  title={An overview on 5α-reductase inhibitors},
  author={Saurabh Aggarwal and Suresh Thareja and Abhilasha Verma and T. Bhardwaj and M. Kumar},
  journal={Steroids},
  year={2010},
  volume={75},
  pages={109-153}
}
  • Saurabh Aggarwal, Suresh Thareja, +2 authors M. Kumar
  • Published 2010
  • Biology, Medicine
  • Steroids
  • Benign prostatic hyperplasia (BPH) is the noncancerous proliferation of the prostate gland associated with benign prostatic obstruction and lower urinary tract symptoms (LUTS) such as frequency, hesitancy, urgency, etc. Its prevalence increases with age affecting around 70% by the age of 70 years. High activity of 5alpha-reductase enzyme in humans results in excessive dihydrotestosterone levels in peripheral tissues and hence suppression of androgen action by 5alpha-reductase inhibitors is a… CONTINUE READING
    157 Citations
    Role of 5α-reductase inhibitors in benign prostatic diseases
    • 14
    • PDF
    Hormonal manipulation of benign prostatic hyperplasia
    • 18
    Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
    • 45

    References

    SHOWING 1-10 OF 202 REFERENCES
    Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    • 15
    Selective non-steroidal inhibitors of 5α-reductase type 1
    • 34
    Novel aromatase and 5α-reductase inhibitors
    • 52
    Effects of 5α-reductase inhibitors on intraprostatic androgens in the rat
    • 13